Advertisement

Gastrointestinal Symptoms: Nausea and Vomiting

  • Bertrand BehmEmail author
  • Carlos Fernandez
  • Mellar P. Davis
Reference work entry

Abstract

This chapter examines nausea and vomiting affecting patients who suffer from serious illness. A deeper understanding of these physiologic processes allows for better assessment and management. There are several different pharmacological and nonpharmacological options to improve palliation, including complementary and alternative medicines. Ultimately, there should be an individualized approach that considers the trajectory of illness and comorbidities, and most importantly it should be patient centered.

References

  1. Aapro M. 5-HT(3)-receptor antagonists in the management of nausea and vomiting in cancer and cancer treatment. Oncology. 2005;69(2):97–109.PubMedCrossRefPubMedCentralGoogle Scholar
  2. American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012;60(4):616–31.CrossRefGoogle Scholar
  3. Amesbury B, Alloway L, Hickmore E, Dewhurst G. High-dose levomepromazine (methotrimeprazine) to control nausea in carcinoid syndrome. J Palliat Care. 2004;20(2):117–8.PubMedCrossRefPubMedCentralGoogle Scholar
  4. Anchin JM, Subramaniam S, Linthicum DS. Binding of the neuroleptic drug haloperidol to a monoclonal antibody: refinement of the binding site molecular model using canonical structures. J Mol Recognit. 1991;4(1):7–15.PubMedCrossRefPubMedCentralGoogle Scholar
  5. Andrews PL, Sanger GJ. Nausea and the quest for the perfect anti-emetic. Eur J Pharmacol. 2014;722:108–21.PubMedCrossRefPubMedCentralGoogle Scholar
  6. Ang SK, Shoemaker LK, Davis MP. Nausea and vomiting in advanced cancer. Am J Hosp Palliat Care. 2010;27(3):219–25.PubMedCrossRefPubMedCentralGoogle Scholar
  7. Atkinson SR. Olanzapine for intractable nausea and vomiting in palliative care patients not receiving chemotherapy. J Palliat Med. 2014;17(5):503–4.PubMedCrossRefPubMedCentralGoogle Scholar
  8. Babic T, Browning KN. The role of vagal neurocircuits in the regulation of nausea and vomiting. Eur J Pharmacol. 2014;722:38–47.PubMedCrossRefPubMedCentralGoogle Scholar
  9. Barkin JS, Goldberg RI, Sfakianakis GN, Levi J. Pancreatic carcinoma is associated with delayed gastric emptying. Dig Dis Sci. 1986;31(3):265–7.PubMedCrossRefPubMedCentralGoogle Scholar
  10. Barr RG, Rowe BG, Camargo CA Jr. Methylxanthines for exacerbation of chronic obstructive pulmonary disease: a meta-analysis of randomised trials. BMJ. 2003;327(7416):643–49.PubMedPubMedCentralCrossRefGoogle Scholar
  11. Bentley A, Boyd K. Use of clinical pictures in the management of nausea and vomiting: a prospective audit. Palliat Med. 2001;15(3):247–53.PubMedCrossRefPubMedCentralGoogle Scholar
  12. Benze G, Alt-Epping B, Geyer A, Nauck F. Treatment of nausea and vomiting with prokinetics and neuroleptics in palliative care patients: a review. Schmerz. 2012;26(5):500–14.PubMedCrossRefPubMedCentralGoogle Scholar
  13. Bliss JM, Robertson B, Selby PJ. The impact of nausea and vomiting upon quality of life measures. Br J Cancer Suppl. 1992;19:S14–22; discussion S3.PubMedPubMedCentralGoogle Scholar
  14. Brooksbank MA, Game PA, Ashby MA. Palliative venting gastrostomy in malignant intestinal obstruction. Palliat Med. 2002;16(6):520–6.PubMedCrossRefPubMedCentralGoogle Scholar
  15. Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K. The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care. 1991;7(2):6–9.PubMedCrossRefPubMedCentralGoogle Scholar
  16. Bruera E, Seifert L, Watanabe S, Babul N, Darke A, Harsanyi Z, et al. Chronic nausea in advanced cancer patients: a retrospective assessment of a metoclopramide-based antiemetic regimen. J Pain Symptom Manag. 1996;11(3):147–53.CrossRefGoogle Scholar
  17. Bruera E, Belzile M, Neumann C, Harsanyi Z, Babul N, Darke A. A double-blind, crossover study of controlled-release metoclopramide and placebo for the chronic nausea and dyspepsia of advanced cancer. J Pain Symptom Manag. 2000;19(6):427–35.CrossRefGoogle Scholar
  18. Bruera E, Moyano JR, Sala R, Rico MA, Bosnjak S, Bertolino M, et al. Dexamethasone in addition to metoclopramide for chronic nausea in patients with advanced cancer: a randomized controlled trial. J Pain Symptom Manag. 2004;28(4):381–8.CrossRefGoogle Scholar
  19. Camilleri M, Parkman HP, Shafi MA, Abell TL, Gerson L. American College of G. Clinical guideline: management of gastroparesis. Am J Gastroenterol. 2013;108(1):18–37; quiz 8.PubMedCrossRefPubMedCentralGoogle Scholar
  20. Campora E, Merlini L, Pace M, Bruzzone M, Luzzani M, Gottlieb A, et al. The incidence of narcotic-induced emesis. J Pain Symptom Manag. 1991;6(7):428–30.CrossRefGoogle Scholar
  21. Chang VT, Hwang SS, Kasimis B, Thaler HT. Shorter symptom assessment instruments: the Condensed Memorial Symptom Assessment Scale (CMSAS). Cancer Investig. 2004;22(4):526–36.CrossRefGoogle Scholar
  22. Chanthawong S, Subongkot S, Sookprasert A. Effectiveness of olanzapine for the treatment of breakthrough chemotherapy induced nausea and vomiting. J Med Assoc Thailand. 2014;97(3):349–55.Google Scholar
  23. Cheung WY, Le LW, Zimmermann C. Symptom clusters in patients with advanced cancers. Support care cancer. 2009;17(9):1223–30.PubMedCrossRefPubMedCentralGoogle Scholar
  24. Chiu L, Chow R, Popovic M, Navari RM, Shumway NM, Chiu N, et al. Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis. Support Care Cancer. 2016;24(5):2381–92.PubMedCrossRefPubMedCentralGoogle Scholar
  25. Clissold SP, Heel RC. Transdermal hyoscine (scopolamine). A preliminary review of its pharmacodynamic properties and therapeutic efficacy. Drugs. 1985;29(3):189–207.PubMedCrossRefPubMedCentralGoogle Scholar
  26. Collis E, Mather H. Nausea and vomiting in palliative care. BMJ. 2015;351:h6249.PubMedCrossRefPubMedCentralGoogle Scholar
  27. Coluzzi F, Rocco A, Mandatori I, Mattia C. Non-analgesic effects of opioids: opioid-induced nausea and vomiting: mechanisms and strategies for their limitation. Curr Pharm Des. 2012;18(37):6043–52.PubMedCrossRefPubMedCentralGoogle Scholar
  28. Cousins SE, Tempest E, Feuer DJ. Surgery for the resolution of symptoms in malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer. Cochrane Database Syst Rev. 2016;1:CD002764.Google Scholar
  29. Cox L, Darvill E, Dorman S. Levomepromazine for nausea and vomiting in palliative care. Cochrane Database Syst Rev. 2015;11:CD009420.Google Scholar
  30. Currow DC, Abernethy AP. Five years’ time and the next five things for the list of choosing wisely. J Palliat Med. 2013;16(6):594–5.PubMedCrossRefPubMedCentralGoogle Scholar
  31. Dahl S, Refsum H. Effects of levomepromazine, chlorpromazine and their sulfoxides on isolated rat atria. Eur J Pharmacol. 1976;37(2):241–8.PubMedCrossRefPubMedCentralGoogle Scholar
  32. Davis MP, Hallerberg G. Palliative Medicine Study Group of the Multinational Association of Supportive Care in C. A systematic review of the treatment of nausea and/or vomiting in cancer unrelated to chemotherapy or radiation. J Pain Symptom Manag. 2010;39(4):756–67.CrossRefGoogle Scholar
  33. Davis MP, Walsh D. Treatment of nausea and vomiting in advanced cancer. Supportive Care Cancer. 2000;8(6):444–52.CrossRefGoogle Scholar
  34. DeEulis TG, Yennurajalingam S. Venting gastrostomy at home for symptomatic management of bowel obstruction in advanced/recurrent ovarian malignancy: a case series. J Palliat Med. 2015;18(8):722–8.PubMedCrossRefPubMedCentralGoogle Scholar
  35. Dietz I, Schmitz A, Lampey I, Schulz C. Evidence for the use of Levomepromazine for symptom control in the palliative care setting: a systematic review. BMC Palliat Care. 2013;12:2.PubMedPubMedCentralCrossRefGoogle Scholar
  36. Diver E, O'Connor O, Garrett L, Boruta D, Goodman A, Del Carmen M, et al. Modest benefit of total parenteral nutrition and chemotherapy after venting gastrostomy tube placement. Gynecol Oncol. 2013;129(2):332–5.PubMedCrossRefPubMedCentralGoogle Scholar
  37. Dolan EA. Malignant bowel obstruction: a review of current treatment strategies. Am J Hosp Palliat Care. 2011;28(8):576–82.PubMedCrossRefPubMedCentralGoogle Scholar
  38. dos Santos LV, Souza FH, Brunetto AT, Sasse AD, da Silveira Nogueira Lima JP. Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review. J Natl Cancer Inst. 2012;104(17):1280–92.PubMedCrossRefPubMedCentralGoogle Scholar
  39. Dossett ML, Davis RB, Lembo AJ, Yeh GY. Complementary and alternative medicine use by US adults with gastrointestinal conditions: results from the 2012 National Health Interview Survey. Am J Gastroenterol. 2014;109(11):1705–11.PubMedPubMedCentralCrossRefGoogle Scholar
  40. Dunn LT. Raised intracranial pressure. J Neurol Neurosurg Psychiatry. 2002;73(Suppl 1):i23–7.PubMedPubMedCentralCrossRefGoogle Scholar
  41. Eisenchlas JH, Garrigue N, Junin M, De Simone GG. Low-dose levomepromazine in refractory emesis in advanced cancer patients: an open-label study. Palliat Med. 2005;19(1):71–5.PubMedCrossRefPubMedCentralGoogle Scholar
  42. Ejskjaer NT, Bradley JL, Buxton-Thomas MS, Edmonds ME, Howard ER, Purewal T, et al. Novel surgical treatment and gastric pathology in diabetic gastroparesis. Diabet med. 1999;16(6):488–95.PubMedCrossRefPubMedCentralGoogle Scholar
  43. Entrena JM, Cobos EJ, Nieto FR, Cendan CM, Baeyens JM, Del Pozo E. Antagonism by haloperidol and its metabolites of mechanical hypersensitivity induced by intraplantar capsaicin in mice: role of sigma-1 receptors. Psychopharmacology. 2009;205(1):21–33.PubMedPubMedCentralCrossRefGoogle Scholar
  44. Farmer AD, Ban VF, Coen SJ, Sanger GJ, Barker GJ, Gresty MA, et al. Visually induced nausea causes characteristic changes in cerebral, autonomic and endocrine function in humans. J Physiol. 2015;593(5):1183–96.PubMedPubMedCentralCrossRefGoogle Scholar
  45. Fletcher DS, Coyne PJ, Dodson PW, Parker GG, Wan W, Smith TJ. A randomized trial of the effectiveness of topical “ABH Gel” (Ativan((R)), Benadryl((R)), Haldol((R))) vs. placebo in cancer patients with nausea. J Pain Symptom Manag. 2014;48(5):797–803.CrossRefGoogle Scholar
  46. Garcia MK, McQuade J, Haddad R, Patel S, Lee R, Yang P, et al. Systematic review of acupuncture in cancer care: a synthesis of the evidence. J Clin Oncol. 2013;31(7):952–60.PubMedPubMedCentralCrossRefGoogle Scholar
  47. Glare P, Pereira G, Kristjanson LJ, Stockler M, Tattersall M. Systematic review of the efficacy of antiemetics in the treatment of nausea in patients with far-advanced cancer. Support Care Cancer. 2004;12(6):432–40.PubMedCrossRefPubMedCentralGoogle Scholar
  48. Glare P, Miller J, Nikolova T, Tickoo R. Treating nausea and vomiting in palliative care: a review. Clin Interv Aging. 2011;6:243–59.PubMedPubMedCentralCrossRefGoogle Scholar
  49. Goodin S, Cunningham R. 5-HT(3)-receptor antagonists for the treatment of nausea and vomiting: a reappraisal of their side-effect profile. Oncologist. 2002;7(5):424–36.PubMedCrossRefPubMedCentralGoogle Scholar
  50. Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW, et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol. 1999;17(9):2971–94.PubMedCrossRefPubMedCentralGoogle Scholar
  51. Greaves J, Glare P, Kristjanson LJ, Stockler M, Tattersall MH. Undertreatment of nausea and other symptoms in hospitalized cancer patients. Support care cancer. 2009;17(4):461–4.PubMedCrossRefPubMedCentralGoogle Scholar
  52. Grimes JD, Hassan MN, Preston DN. Adverse neurologic effects of metoclopramide. Can Med Assoc J. 1982;126(1):23–5.PubMedPubMedCentralGoogle Scholar
  53. Gupta D, Mazumdar A, Stellini M. A physiological perspective for utility or futility of alcohol-based hand rub gel against nausea-vomiting: is it P-6 acupoint or transnasal aroma? Am J Hosp Palliat Care. 2014;31(6):608–10.PubMedCrossRefPubMedCentralGoogle Scholar
  54. Hafermann MJ, Namdar R, Seibold GE, Page RL 2nd. Effect of intravenous ondansetron on QT interval prolongation in patients with cardiovascular disease and additional risk factors for torsades: a prospective, observational study. Drug Healthcare Patient Safety. 2011;3:53–8.Google Scholar
  55. Hardy J, Daly S, McQuade B, Albertsson M, Chimontsi-Kypriou V, Stathopoulos P, et al. A double-blind, randomised, parallel group, multinational, multicentre study comparing a single dose of ondansetron 24 mg p.o. with placebo and metoclopramide 10 mg t.d.s. p.o. in the treatment of opioid-induced nausea and emesis in cancer patients. Support Care Cancer. 2002;10(3):231–6.PubMedCrossRefPubMedCentralGoogle Scholar
  56. Hardy JR, O'Shea A, White C, Gilshenan K, Welch L, Douglas C. The efficacy of haloperidol in the management of nausea and vomiting in patients with cancer. J Pain Symptom Manag. 2010;40(1):111–6.CrossRefGoogle Scholar
  57. Hasler WL. Pathology of emesis: its autonomic basis. Handb Clin Neurol. 2013;117:337–52.PubMedCrossRefPubMedCentralGoogle Scholar
  58. Hatta K, Takahashi T, Nakamura H, Yamashiro H, Asukai N, Matsuzaki I, et al. The association between intravenous haloperidol and prolonged QT interval. J Clin Psychopharmacol. 2001;21(3):257–61.PubMedCrossRefPubMedCentralGoogle Scholar
  59. Helmeste DM, Seeman P. [3H]haloperidol binding to more than one site in rat brain striatum. Biochem Pharmacol. 1983;32(4):741–4.PubMedCrossRefPubMedCentralGoogle Scholar
  60. Hisanaga T, Shinjo T, Morita T, Nakajima N, Ikenaga M, Tanimizu M, et al. Multicenter prospective study on efficacy and safety of octreotide for inoperable malignant bowel obstruction. Jpn J Clin Oncol. 2010;40(8):739–45.PubMedCrossRefPubMedCentralGoogle Scholar
  61. Ho CM, Ho ST, Wang JJ, Tsai SK, Chai CY. Dexamethasone has a central antiemetic mechanism in decerebrated cats. Anesth Analg. 2004;99(3):734–9; table of contents.PubMedCrossRefPubMedCentralGoogle Scholar
  62. Horn CC. Why is the neurobiology of nausea and vomiting so important? Appetite. 2008;50(2–3):430–4.PubMedCrossRefPubMedCentralGoogle Scholar
  63. Hornby PJ. Central neurocircuitry associated with emesis. Am J Med. 2001;111(Suppl 8A):106S–12S.PubMedCrossRefPubMedCentralGoogle Scholar
  64. Hussain ZH, Whitehead DA, Lacy BE. Fecal impaction. Curr Gastroenterol Rep. 2014;16(9):404.PubMedCrossRefPubMedCentralGoogle Scholar
  65. Issaka RB, Shapiro DM, Parikh ND, Mulcahy MF, Komanduri S, Martin JA, et al. Palliative venting percutaneous endoscopic gastrostomy tube is safe and effective in patients with malignant obstruction. Surg Endosc. 2014;28(5):1668–73.PubMedCrossRefPubMedCentralGoogle Scholar
  66. Jordan K, Sippel C, Schmoll HJ. Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations. Oncologist. 2007;12(9):1143–50.PubMedCrossRefPubMedCentralGoogle Scholar
  67. Kaneishi K, Nishimura K, Sakurai N, Imai K, Matsuo N, Takahashi N, et al. Use of olanzapine for the relief of nausea and vomiting in patients with advanced cancer: a multicenter survey in Japan. Support Care Cancer. 2016;24(6):2393–5.PubMedCrossRefPubMedCentralGoogle Scholar
  68. Kennett A, Hardy J, Shah S, A'Hern R. An open study of methotrimeprazine in the management of nausea and vomiting in patients with advanced cancer. Support Care Cancer. 2005;13(9):715–21.PubMedCrossRefPubMedCentralGoogle Scholar
  69. Kirkova J, Rybicki L, Walsh D, Aktas A. Symptom prevalence in advanced cancer: age, gender, and performance status interactions. Am J Hosp Palliat Care. 2012;29(2):139–45.PubMedCrossRefPubMedCentralGoogle Scholar
  70. Laval G, Marcelin-Benazech B, Guirimand F, Chauvenet L, Copel L, Durand A, et al. Recommendations for bowel obstruction with peritoneal carcinomatosis. J Pain Symptom Manag. 2014;48(1):75–91.CrossRefGoogle Scholar
  71. Lee A, Kuo B. Metoclopramide in the treatment of diabetic gastroparesis. Expert Rev endocrinol Metabol. 2010;5(5):653–62.CrossRefGoogle Scholar
  72. Lee A, Chan SK, Fan LT. Stimulation of the wrist acupuncture point PC6 for preventing postoperative nausea and vomiting. Cochrane Database Syst Rev. 2015;11:CD003281.PubMedCentralGoogle Scholar
  73. Machado Rocha FC, Stefano SC, De Cassia Haiek R, Rosa Oliveira LM, Da Silveira DX. Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. Eur J Cancer Care. 2008;17(5):431–43.CrossRefGoogle Scholar
  74. MacKintosh D. Olanzapine in the management of difficult to control nausea and vomiting in a palliative care population: a case series. J Palliat Med. 2016;19(1):87–90.PubMedCrossRefPubMedCentralGoogle Scholar
  75. Marx W, Kiss N, Isenring L. Is ginger beneficial for nausea and vomiting? An update of the literature. Curr Opin Support Palliat Care. 2015;9(2):189–95.PubMedCrossRefPubMedCentralGoogle Scholar
  76. Mayer EA, Tillisch K, Ellingson BM. Dyspepsia: structural changes in functional gastrointestinal disorders. Nat Rev Gastroenterol Hepatol. 2013;10(4):200–2.PubMedCrossRefPubMedCentralGoogle Scholar
  77. Meiri E, Jhangiani H, Vredenburgh JJ, Barbato LM, Carter FJ, Yang HM, et al. Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Curr Med Res Opin. 2007;23(3):533–43.PubMedCrossRefPubMedCentralGoogle Scholar
  78. Molassiotis A, Russell W, Hughes J, Breckons M, Lloyd-Williams M, Richardson J, et al. The effectiveness of acupressure for the control and management of chemotherapy-related acute and delayed nausea: a randomized controlled trial. J Pain Symptom Manag. 2014;47(1):12–25.CrossRefGoogle Scholar
  79. Moradian S, Walshe C, Shahidsales S, Ghavam Nasiri MR, Pilling M, Molassiotis A. Nevasic audio program for the prevention of chemotherapy induced nausea and vomiting: a feasibility study using a randomized controlled trial design. Eur J Oncol Nurs. 2015;19(3):282–91.PubMedCrossRefPubMedCentralGoogle Scholar
  80. Mystakidou K, Befon S, Liossi C, Vlachos L. Comparison of tropisetron and chlorpromazine combinations in the control of nausea and vomiting of patients with advanced cancer. J Pain Symptom Manag. 1998;15(3):176–84.CrossRefGoogle Scholar
  81. Napadow V, Sheehan JD, Kim J, Lacount LT, Park K, Kaptchuk TJ, et al. The brain circuitry underlying the temporal evolution of nausea in humans. Cereb Cortex. 2013;23(4):806–13.PubMedCrossRefPubMedCentralGoogle Scholar
  82. Navari RM, Brenner MC. Treatment of cancer-related anorexia with olanzapine and megestrol acetate: a randomized trial. Support Care Cancer. 2010;18(8):951–6.PubMedCrossRefPubMedCentralGoogle Scholar
  83. Navari RM, Einhorn LH, Loehrer PJ Sr, Passik SD, Vinson J, McClean J, et al. A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study. Support Care Cancer. 2007;15(11):1285–91.PubMedCrossRefPubMedCentralGoogle Scholar
  84. Navari RM, Brenner MC, Wilson MN. Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy. Breast Cancer Res Treat. 2008;112(1):197–201.PubMedCrossRefPubMedCentralGoogle Scholar
  85. O'Grady G, Egbuji JU, Du P, Cheng LK, Pullan AJ, Windsor JA. High-frequency gastric electrical stimulation for the treatment of gastroparesis: a meta-analysis. World J Surg. 2009;33(8):1693–701.PubMedPubMedCentralCrossRefGoogle Scholar
  86. O'Grady G, Wang TH, Du P, Angeli T, Lammers WJ, Cheng LK. Recent progress in gastric arrhythmia: pathophysiology, clinical significance and future horizons. Clin Exp Pharmacol Physiol. 2014;41(10):854–62.PubMedPubMedCentralCrossRefGoogle Scholar
  87. Pan CX, Morrison RS, Ness J, Fugh-Berman A, Leipzig RM. Complementary and alternative medicine in the management of pain, dyspnea, and nausea and vomiting near the end of life. A systematic review. J Pain Symptom Manag. 2000;20(5):374–87.CrossRefGoogle Scholar
  88. Parker LA, Rock EM, Limebeer CL. Regulation of nausea and vomiting by cannabinoids. Br J Pharmacol. 2011;163(7):1411–22.PubMedPubMedCentralCrossRefGoogle Scholar
  89. Passik SD, Lundberg J, Kirsh KL, Theobald D, Donaghy K, Holtsclaw E, et al. A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. J Pain Symptom Manag. 2002;23(6):526–32.CrossRefGoogle Scholar
  90. Passik SD, Navari RM, Jung SH, Nagy C, Vinson J, Kirsh KL, et al. A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study. Cancer Investig. 2004;22(3):383–8.CrossRefGoogle Scholar
  91. Patt RB. Pharmacotherapy for cancer pain: an anaesthesiologist’s viewpoint. Ann Acad Med Singap. 1994;23(4):598–609.PubMedPubMedCentralGoogle Scholar
  92. Pertwee RG. Pharmacology of cannabinoid receptor ligands. Curr Med Chem. 1999;6(8):635–64.PubMedPubMedCentralGoogle Scholar
  93. Pyykko I, Padoan S, Schalen L, Lyttkens L, Magnusson M, Henriksson NG. The effects of TTS-scopolamine, dimenhydrinate, lidocaine, and tocainide on motion sickness, vertigo, and nystagmus. Aviat Space Environ Med. 1985;56(8):777–82.PubMedPubMedCentralGoogle Scholar
  94. Richards CA, Andrews PL. Emesis as a model system for the study of functional bowel disease. J Pediatr Gastroenterol Nutr. 2007;45(Suppl 2):S120–6.PubMedCrossRefPubMedCentralGoogle Scholar
  95. Richards DM, Tanikella R, Arora G, Guha S, Dekovich AA. Percutaneous endoscopic gastrostomy in cancer patients: predictors of 30-day complications, 30-day mortality, and overall mortality. Dig Dis Sci. 2013;58(3):768–76.PubMedCrossRefPubMedCentralGoogle Scholar
  96. Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, et al. MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol. 2016;27(Suppl 5):v119–v33.PubMedCrossRefPubMedCentralGoogle Scholar
  97. Rojas C, Slusher BS. Pharmacological mechanisms of 5-HT(3) and tachykinin NK(1) receptor antagonism to prevent chemotherapy-induced nausea and vomiting. Eur J Pharmacol. 2012;684(1–3):1–7.PubMedCrossRefPubMedCentralGoogle Scholar
  98. Romero L, Merlos M, Vela JM. Antinociception by Sigma-1 receptor antagonists: central and peripheral effects. Adv Pharmacol. 2016;75:179–215.PubMedCrossRefPubMedCentralGoogle Scholar
  99. Salpeter SR, Buckley JS, Bruera E. The use of very-low-dose methadone for palliative pain control and the prevention of opioid hyperalgesia. J Palliat Med. 2013;16(6):616–22.PubMedPubMedCentralCrossRefGoogle Scholar
  100. Sclocco R, Citi L, Garcia RG, Cerutti S, Bianchi AM, Kuo B, et al. Combining sudomotor nerve impulse estimation with fMRI to investigate the central sympathetic response to nausea. Conference proceedings: Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Annual Conference 2015;2015:4683–4686.Google Scholar
  101. Shaw C, Bassett RL, Fox PS, Schmeler KM, Overman MJ, Wallace MJ, et al. Palliative venting gastrostomy in patients with malignant bowel obstruction and ascites. Ann Surg Oncol. 2013;20(2):497–505.PubMedCrossRefPubMedCentralGoogle Scholar
  102. Sherman MA, Bolger MB. Haloperidol binding to monoclonal antibodies. Predictions of three-dimensional combining site structure via computer modeling. J Biol Chem. 1988;263(9):4064–74.PubMedPubMedCentralGoogle Scholar
  103. Singh P, Yoon SS, Kuo B. Nausea: a review of pathophysiology and therapeutics. Ther Adv Gastroenterol. 2016;9(1):98–112.CrossRefGoogle Scholar
  104. Slatkin NE. Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting: beyond prevention of acute emesis. J Support Oncol. 2007;5(Suppl 3):1–9.PubMedPubMedCentralGoogle Scholar
  105. Smith HS, Laufer A. Opioid induced nausea and vomiting. Eur J Pharmacol. 2014;722:67–78.PubMedCrossRefPubMedCentralGoogle Scholar
  106. Smith LA, Azariah F, Lavender VT, Stoner NS, Bettiol S. Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. Cochrane Database Syst Rev. 2015;11:CD009464.Google Scholar
  107. Solano JP, Gomes B, Higginson IJ. A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease. J Pain Symptom Manag. 2006;31(1):58–69.CrossRefGoogle Scholar
  108. Stanghellini V, Talley NJ, Chan F, Hasler WL, Malagelada J, Suzuki H, et al. Rome IV – Gastroduodenal disorders. Gastroenterology. 2016;150(6):1380–1392.PubMedCrossRefPubMedCentralGoogle Scholar
  109. Steinhoff MS, von Mentzer B, Geppetti P, Pothoulakis C, Bunnett NW. Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease. Physiol Rev. 2014;94(1):265–301.PubMedPubMedCentralCrossRefGoogle Scholar
  110. Stephenson J, Davies A. An assessment of aetiology-based guidelines for the management of nausea and vomiting in patients with advanced cancer. Support Care Cancer. 2006;14(4):348–53.PubMedCrossRefPubMedCentralGoogle Scholar
  111. Stern RM. The psychophysiology of nausea. Acta Biol Hung. 2002;53(4):589–99.PubMedCrossRefPubMedCentralGoogle Scholar
  112. Tageja N, Groninger H. Chemotherapy-induced nausea and vomiting: an overview and comparison of three consensus guidelines. Postgrad Med J. 2016;92(1083):34–40.PubMedCrossRefPubMedCentralGoogle Scholar
  113. Teriaky A, Gregor J, Chande N. Percutaneous endoscopic gastrostomy tube placement for end-stage palliation of malignant gastrointestinal obstructions. Saudi J Gastroenterol. 2012;18(2):95–8.PubMedPubMedCentralCrossRefGoogle Scholar
  114. Thosani S, Hu MI. Denosumab: a new agent in the management of hypercalcemia of malignancy. Future Oncol. 2015;11(21):2865–71.PubMedPubMedCentralCrossRefGoogle Scholar
  115. Tytgat GN. Hyoscine butylbromide: a review of its use in the treatment of abdominal cramping and pain. Drugs. 2007;67(9):1343–57.PubMedCrossRefPubMedCentralGoogle Scholar
  116. Vanaki Z, Matourypour P, Gholami R, Zare Z, Mehrzad V, Dehghan M. Therapeutic touch for nausea in breast cancer patients receiving chemotherapy: composing a treatment. Complement Ther Clin Pract. 2016;22:64–8.PubMedCrossRefPubMedCentralGoogle Scholar
  117. Walsh D, Davis M, Ripamonti C, Bruera E, Davies A, Molassiotis A. 2016 Updated MASCC/ESMO consensus recommendations: management of nausea and vomiting in advanced cancer. Support Care Cancer. 2017;25(1):333–40.PubMedCrossRefPubMedCentralGoogle Scholar
  118. Watari H, Hosaka M, Wakui Y, Nomura E, Hareyama H, Tanuma F, et al. A prospective study on the efficacy of octreotide in the management of malignant bowel obstruction in gynecologic cancer. Int J Gynecol Cancer. 2012;22(4):692–6.PubMedCrossRefPubMedCentralGoogle Scholar
  119. Watkins PJ, Buxton-Thomas MS, Howard ER. Long-term outcome after gastrectomy for intractable diabetic gastroparesis. Diabet Med. 2003;20(1):58–63.PubMedCrossRefPubMedCentralGoogle Scholar
  120. Yuan CS, Foss JF, O'Connor M, Osinski J, Roizen MF, Moss J. Effects of intravenous methylnaltrexone on opioid-induced gut motility and transit time changes in subjects receiving chronic methadone therapy: a pilot study. Pain. 1999;83(3):631–5.PubMedCrossRefPubMedCentralGoogle Scholar
  121. Zhao XD, Cai BB, Cao RS, Shi RH. Palliative treatment for incurable malignant colorectal obstructions: a meta-analysis. World J Gastroenterol. 2013;19(33):5565–74.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Bertrand Behm
    • 1
    Email author
  • Carlos Fernandez
    • 1
  • Mellar P. Davis
    • 2
  1. 1.Palliative MedicineGeisinger Health SystemDanvilleUSA
  2. 2.Department of Palliative CareGeisinger Medical CenterDanvilleUSA

Personalised recommendations